Cytodyn Inc (CYDY)

[DonDonDonDon]

Did not the GLAXO (BP) GM-CSF Covid drug recently fail is Covid19 trial?

At first they said that. But then they decided it needs more study. My guess is that someone went to them behind the scenes and told them about the GM-CSF findings before they were made public. My guess is that they'll do another government funded trial with higher dosage. HGEN's lenzilumab did their trials with a far higher dosage.

https://www.gsk.com/en-gb/media/press-releases/gsk-announces-otilimab-data-for-treatment-of-covid-19/

a pre-planned efficacy analysis by age in patients 70 years and older (N=180, 806 in total study) showed that 65.1% of patients were alive and free of respiratory failure 28 days after treatment with otilimab plus standard of care, compared to 45.9% of patients who received the standard of care alone (delta of 19.1%, 95% CI=5.2%, 33.1%) (nominal p-value=0.009). In addition, in a mortality analysis up to day 60, a treatment difference of 14.4% favouring otilimab was seen with rates of 40.4% on standard of care vs. 26% on otilimab plus standard of care (95% CI= 0.9%, 27.9%) (nominal p-value=0.040) in patients 70 years and older.

Given these data suggest a potentially important clinical benefit in a pre-defined sub-group of high-risk patients and the public health need, GSK has decided to amend the OSCAR study to expand this cohort to confirm these potentially significant findings.